Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations is a research paper published in Journal of Thoracic Oncology (2020). On theSindex it has a DataRank of 0.646. It has been cited 73 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.646
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy
Grant: RP150535
University of Texas MD Anderson Cancer Center
Grant: P30 CA016672
National Cancer Institute
Grant: R01CA169338
National Cancer Institute
Grant: R01CA204302
National Cancer Institute
Grant: R01CA211052
National Cancer Institute
Grant: U01CA217882
National Cancer Institute
Grant: U54CA224081
NCI NIH HHS
Grant: P50 CA070907
National Institutes of Health
Grant: 3U54CA224081-01S1
Bay Area Team Against Resistance
National Institutes of Health
Grant: 3P50CA070907-02S1
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCER
National Institutes of Health
Grant: 1R01CA204302-01A1
Characterization of YAP as a rational companion target in lung cancer
National Institutes of Health
Grant: 5R01CA211052-03
Optimizing biologically-based rational polytherapy in ALK+ lung cancer
National Institutes of Health
Grant: 1U01CA217882-01
The Cancer Target Discovery and Development Network at UCSF
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5R01CA169338-02
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment
Pfizer
Roche
Samsung
Bayer Corporation
AstraZeneca
Genentech
North Carolina GlaxoSmithKline Foundation
Daiichi Sankyo Company
Mayo Clinic
Merck
Spectrum Pharmaceuticals
Bristol-Myers Squibb
F. Hoffmann-La Roche
National Institutes of Health
Bayer HealthCare
Eli Lilly and Company
Novartis
Takeda Pharmaceutical Company
FWCI
3.06
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals